%PDF-1.4
%
19 0 obj
<>
endobj
16 0 obj
<>
endobj
68 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-04-09T16:56:15Z
2024-03-28T21:39:02-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T21:39:02-07:00
application/pdf
Heather
2002-941.omeract.may
uuid:65eaaf48-1dd2-11b2-0a00-8608271d5700
uuid:65eaaf4a-1dd2-11b2-0a00-bf0000000000
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
74 0 obj
[78 0 R]
endobj
75 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0379 Tw 10 0 0 10 54 713.1616 Tm
(state for a period of time leads to benefits in terms of func-)Tj
0.02499 Tw 0 -1.2 TD
(tional disability and structural damage.)Tj
/T1_1 1 Tf
-0.0002 Tc 0 Tw 0 -2.4 TD
(Objectives)Tj
/T1_0 1 Tf
-0.00011 Tc 0.13361 Tw 0 -1.2 TD
(The objectives of this workshop are designed to meet the)Tj
0.21629 Tw T*
(many challenges that exist in determining a low disease)Tj
0.02499 Tw T*
(activity state:)Tj
-0.00529 Tw T*
[(1. )17.7 (T)69.9 (o review the concepts and terminologies associated with)]TJ
0.02499 Tw T*
(a low disease activity state.)Tj
0.0157 Tw T*
[(2. )17.7 (T)69.9 (o determine the processes for developing an operational)]TJ
0.02499 Tw T*
(definition of low disease activity state.)Tj
-0.02631 Tw T*
[(3. )17.8 (T)69.9 (o review and design longitudinal datasets useful for vali-)]TJ
0.02499 Tw T*
(dating a low disease activity state.)Tj
/T1_1 1 Tf
0.00729 Tw 0 -2.4 TD
[(The W)54.8 (orkshop )-17.7 (Pr)17.7 (ocess)]TJ
/T1_0 1 Tf
0.1151 Tw 0 -1.2 TD
(In addition to the above introduction and rationale for the)Tj
0.27541 Tw T*
(definition of a low disease activity state, a background)Tj
0.07069 Tw T*
(article was made available to workshop participants on the)Tj
0.061 Tw T*
(methods and procedures for deriving an operational defini-)Tj
0.02499 Tw T*
(tion of low disease activity state)Tj
0 Tc 0 Tw 6.5 0 0 6.5 183.817 488.4616 Tm
(1)Tj
10 0 0 10 187.0669 485.1616 Tm
(.)Tj
-0.00011 Tc 0.06371 Tw -12.1067 -1.2 Td
(The workshop began with a plenary session introducing)Tj
0.164 Tw -1.2 -1.2 Td
(the objectives and reviewing the concepts and terminolo-)Tj
0.34419 Tw T*
[(gies. In particular)39.7 (, concepts and terminologies such as)]TJ
0.116 Tw T*
(reduction in signs and symptoms, major clinical response,)Tj
0.0199 Tc 0.4254 Tw T*
(complete clinical response, remission, prevention of)Tj
-0.00011 Tc 0.12199 Tw T*
[(disability)64.8 (, and prevention of structural damage were clari-)]TJ
-0.0322 Tw T*
(fied; and the role of time and disease duration were critically)Tj
0 Tw T*
(reviewed.)Tj
0.31509 Tw 1.2 -1.2 Td
(Participants were then divided into breakout groups.)Tj
-0.0177 Tw -1.2 -1.2 Td
(They were able to select from 1 of 4 groups designed to take)Tj
0.1888 Tw T*
(their current interests into consideration as they relate to)Tj
0.0105 Tw T*
[(developing an operational definition of low disease activity)64.8 (.)]TJ
0.0031 Tc 0.3718 Tw T*
(The MCID working group believes that developing a)Tj
-0.00011 Tc 0.0085 Tw T*
(research agenda for such an operational definition is critical)Tj
-0.033 Tw T*
(and these breakout sessions will result in setting a successful)Tj
0.0002 Tw T*
[(agenda. )17.7 (The 4 breakout groups each had a separate goal and)]TJ
0.02499 Tw T*
(focus of interest.)Tj
/T1_2 1 Tf
0 Tc 0.14079 Tw 0 -1.44 TD
[(Gr)36.9 (oup 1. )]TJ
/T1_0 1 Tf
-0.00011 Tc [0.1 (Group 1 considered low disease activity from a)]TJ
0.0004 Tw 0 -1.2 TD
[(patient perspective. )17.7 (V)110.8 (arious patient scenarios were critically)]TJ
0.01939 Tw T*
(reviewed and discussed by the participants, with the goal to)Tj
0.3701 Tw T*
(ensure that any definition takes into consideration the)Tj
0.02499 Tw T*
(patient perspective and ultimately is acceptable to patients.)Tj
/T1_2 1 Tf
0 Tc -0.0322 Tw 0 -1.44 TD
[(Gr)36.9 (oup 2. )]TJ
/T1_0 1 Tf
-0.00011 Tc [0.1 (Group 2 considered the methods and the consensus)]TJ
0.01669 Tw 0 -1.2 TD
(process that can be used for developing an operational defi-)Tj
0.2363 Tw T*
[(nition of low disease activity)64.8 (. )54.8 (A)-431.4 (wide range of possible)]TJ
0.0802 Tw T*
(judgmental and statistical approaches were discussed, with)Tj
0.01489 Tc 0.36 Tw 26.4 54.48 Td
(the goal to develop a comprehensive methodological)Tj
-0.00011 Tc 0.02271 Tw T*
(strategy to be implemented for the development of an oper-)Tj
0.02499 Tw T*
(ational definition.)Tj
/T1_2 1 Tf
0 Tc 0.0462 Tw 0 -1.44 TD
[(Gr)36.9 (oup 3. )]TJ
/T1_0 1 Tf
-0.00011 Tc [0.2 (Group 3 reviewed measures that could be used in)]TJ
0.1254 Tw 0 -1.2 TD
[(the definition of a low disease activity)64.8 (. Starting with core)]TJ
0.1815 Tw T*
[(measures used in indexes such as the )54.8 (ACR20 \(American)]TJ
0.0159 Tc 0.35899 Tw T*
(College of Rheumatology remission criteria\) and the)Tj
-0.00011 Tc 0.11749 Tw T*
[(Disease )54.9 (Activity Score, participants reviewed other poten-)]TJ
0.0034 Tw T*
(tial measures, such as fatigue, with the goal of drawing up a)Tj
0.0015 Tw T*
(comprehensive and parsimonious list of candidate measures)Tj
0.02499 Tw T*
(for use in a definition.)Tj
/T1_2 1 Tf
0 Tc 0.25191 Tw 0 -1.44 TD
[(Gr)36.9 (oup 4. )]TJ
/T1_0 1 Tf
-0.00011 Tc [0.2 (Group 4 reviewed actual definitions of a low)]TJ
0.1389 Tw 0 -1.2 TD
[(disease activity state. )17.7 (The measures that were included in)]TJ
0.08099 Tw T*
(the definition were given, and participants focussed on the)Tj
0.0349 Tw T*
(levels and combinations of the measures used in the defini-)Tj
0.1149 Tw T*
(tion with the goal of providing examples of definitions of)Tj
0.02499 Tw T*
[(low disease activity state that have face validity)64.8 (.)]TJ
0.0024 Tc 0.3725 Tw 1.2 -1.2 Td
(Each group generated a report from their breakout)Tj
-0.00011 Tc -0.07809 Tw -1.2 -1.2 Td
(session. A)Tj
/T1_2 1 Tf
0 Tc 0 Tw 4.204 0 Td
(rapporteur)Tj
/T1_0 1 Tf
-0.00011 Tc -0.02319 Tw 4.6152 0 Td
(for each breakout group reported back)Tj
0.0719 Tw -8.8192 -1.2 Td
[(in a closing workshop plenary)64.8 (. )17.7 (The reports of the breakout)]TJ
0.07069 Tw T*
(groups were centered on specific questions such that when)Tj
0.2885 Tw T*
[(mer)17.7 (ged they would provide a framework of a research)]TJ
0.01331 Tw T*
(agenda for developing an operational definition low disease)Tj
0.0697 Tw T*
[(activity state. )17.7 (This framework was presented at the confer-)]TJ
0.02499 Tw T*
[(ence plenary)64.8 (. )]TJ
0.1185 Tw 1.2 -1.2 Td
(Other reports will result from this workshop. In partic-)Tj
0.3502 Tw -1.2 -1.2 Td
[(ular)39.7 (, a research agenda for determining a low disease)]TJ
0.0011 Tw T*
(activity state and issues related to prospectively validating a)Tj
0.02499 Tw T*
(definition of low disease activity state are planned.)Tj
/T1_1 1 Tf
-0.0002 Tc 0 Tw 0 -2.4 TD
(Outcomes)Tj
/T1_0 1 Tf
-0.00011 Tc 0.1611 Tw 0 -1.2 TD
(The anticipated outcome of the workshop was a research)Tj
0.1817 Tw T*
(agenda for developing an operational definition of a low)Tj
0.0845 Tw T*
(disease activity state)Tj
0 Tc 0 Tw 6.5 0 0 6.5 401.8751 315.6617 Tm
(2)Tj
-0.00011 Tc 0.0845 Tw 10 0 0 10 405.125 312.3616 Tm
[(. )17.7 (This research agenda will be imple-)]TJ
0.045 Tw -8.7125 -1.2 Td
[(mented and conducted after OMERACT)-277.4 (6 with the presen-)]TJ
0.1581 Tw T*
(tation of the results and consensus building as a possible)Tj
0.02499 Tw T*
[(module for OMERACT)-257.3 (7.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 242.3616 Tm
[(1.)-875.1 (Boers M, )54.8 (Anderson JJ, Felson D. Deriving an operational definition)]TJ
1.675 -1.25 Td
(of low disease activity state in rheumatoid arthritis. J Rheumatol)Tj
0 Tc 0 Tw 0 -1.25 TD
[(2003;30:1)36.9 (1)36.9 (17-9.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (W)79.9 (ells GA, )54.8 (Anderson JJ, Boers M, et al. Minimal Clinically)]TJ
1.675 -1.25 Td
[(Important Dif)17.7 (ference/Low Disease )54.8 (Activity State )17.7 (W)79.9 (orkshop.)]TJ
T*
[(Summary)64.9 (, recommendations, and research agenda. J Rheumatol)]TJ
0 Tc 0 Tw T*
[(2003;30:1)36.9 (120-3.)]TJ
ET
0 0 0 0 scn
420 777 137 -27 re
f*
408 770 150 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(W)91.9 (ells, et al: Defining RA)-257.3 (impr)36.8 (ovement)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1111)Tj
ET
0 0 0 0 scn
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
22 0 obj
<>
endobj
63 0 obj
<>
endobj
73 0 obj
<>
endobj
23 0 obj
<>
endobj
58 0 obj
<>stream
H{PSw%ܛbTUkZw-U"< Q "bP@wW[]Sagq{nӍؙu͜9sssp
q|zА"R|&P"N|_`l}ˍagy猇;+ ĜfփS`hZlzOqozY*]/Y,LtJ& I bv
TlJI҅
Q/H$xIE.81#3BF.LI^&D"SRELFFDΈ]yre\$Er_w;~1uI6ya>86o
ֺD8 |>
?3>}{'FL3>q⤉'LQrGxKx)OɴC<%_ӟgT$fFkWo;돃x`/)V+EA!m=RgJ,Gͮ0UZsGKU5C2Iiak+gk{UkE%Ps^mbNi5:eNl{Y֞_!L-2JΥVrsSty-G\AKh7*
2zSnba2b cT;ʹ<3W[҆,*W`WSTJY9z ېc!BF^-+Pe2R6ڒ<e4J%#!HZZp.:g1UzZ4#
ͷS8%VSwPG>
~0-SF =tʜPf4--@X2'?B)>_zi#_=x6A\B65յK\bPڸ qsB+~~Ï_sy0Vh%]SũJ}Sft;r+WBKyԗ+G#pdC'rypJq8!醦3MN:/IV^/7 'RyH۩O7*
r
y˵'7»
ϛyH
Vy6/HKņ(b,FJ9`
Q6ʆ91HC5B7IVI
R**r:TAh 0b[{Aw9ٳ] wN8k@-ihMwDQa0_F
ړ:7^I~L_Ə
a>>/,_+3[Q~EWGGs/Nݣ͎}gMO7وqkd#P5&@;i΅6#@"Xjqa3xc.9J?mnazmih(45fRߠM>f3n/qTS<Rl5qNuхyaU^*sLIC Qhfr@|y/W5[l]
D>6L
̸䛣vⅨѯ6J8m89`_7rAa!,>&F9>A[Cr̼,w7 _MmiUV`;ycȵ^YA`IaJ26K&78b2uP+,!Ƥ$Mlw$?Pc4ӈ((+
\S
r^<0G#4#88*?^|Vj7%2X'p<6ׁ'ԝF1պJAƮ:[.u>XEQGP;@^@ !&
"
.ʺHݪ27u||ww~;bC
/N`Å^8IU@;nEpey:6wFn]$#f 8C"c]D?
p5D>KW`
4Xt=t
7BIEj}S#S@Gv|7(e Je%ۈD{2=H7J'q*9$bCo)/M ,
J0nPFhxA׳%5S7.S!,zH:aPHB{;,^=Y262LiH3=~
N@>BܝK\ ؗQze(FG{f8y^EK5Z4R^A*ڈsш_*%t
ũ.;06`SmKK_;yT5:g5SUW‥D08Osjܫ=
=lUIz!2@̆('J^Q B3eYC<{
yz ;\v%'n=`uŌ\݇>\'q`jx*&l?FdX>wY6ٕ}^?t,4
W{mbCXQL:Cꦤ&:;}x%-|